Oral Vaccine Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on Oral Vaccine Market 

5.1. COVID-19 Landscape: Oral Vaccine Industry Impact

5.2. COVID-19 - Impact Assessment for the Industry

5.3. COVID-19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oral Vaccine Market, By Vaccines Type

8.1. Oral Vaccine Market Revenue and Volume Forecast, by Vaccines Type, 2024-2034

8.1.1. Live Attenuated Vaccines

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Inactivated Vaccines

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Subunit Vaccines

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global Oral Vaccine Market, By Application

9.1. Oral Vaccine Market Revenue and Volume Forecast, by Application, 2024-2034

9.1.1. Infectious Diseases

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. Cancer

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global Oral Vaccine Market, By Distribution Channel

10.1. Oral Vaccine Market Revenue and Volume Forecast, by Distribution Channel, 2024-2034

10.1.1. Hospital

10.1.1.1. Market Revenue and Volume Forecast (2021-2034)

10.1.2. Clinics

10.1.2.1. Market Revenue and Volume Forecast (2021-2034)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Volume Forecast (2021-2034)

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 11. Global Oral Vaccine Market, By End-User 

11.1. Oral Vaccine Market Revenue and Volume Forecast, by End-User, 2024-2034

11.1.1. Paediatrics

11.1.1.1. Market Revenue and Volume Forecast (2021-2034)

11.1.2. Adults

11.1.2.1. Market Revenue and Volume Forecast (2021-2034)

11.1.3. Geriatrics

11.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 12. Global Oral Vaccine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.1.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.1.5.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.1.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.1.6.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.2.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.2.5.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.2.6.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.2.7.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.2.8.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.8.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.2.8.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.3.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.3.5.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.3.6.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.3.7.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.3.8.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.3.8.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.4.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.4.5.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.4.6.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.4.7.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.4.8.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.4.8.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.5.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.5.5.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2021-2034)

12.5.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

12.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)

12.5.6.4. Market Revenue and Volume Forecast, by End-User (2021-2034)

Chapter 13. Company Profiles

13.1. Sanofi

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GSK

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. IOS

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Takeda Pharmaceuticals

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Soligenix

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Liquidia Technologies

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Elasmogen

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Abivax

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Oravax Medical

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Rapid Dose Therapeutics

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms